/  - Rob van der Heijden, Bruker

Rob van der Heijden, Bruker

New levels in speed and robustness in MALDI-MS for demanding applications; tissue imaging and high-throughput screening for Drug Discovery

During 25 years of commercial development, MALDI-MS became and remained the method of choice for a range of applications. In particular in proteomics, intact protein analysis  (biopharmaceuticals),  polymer characterization, microbiology (identification) and pathology  (imaging),  MALDI-MS plays an essential and predominant role in present-day  R&D and routine applications. Its popularity is not only based on its excellent technical performance, but certainly also based on its ease of use, speed and robustness. Some modern applications however, demand extraordinary performance in speed and robustness because of the extreme number of spectra to be collected. For example in MALDI imaging a tissue is scanned with the laser and every pixel in the image requires the acquisition of numerous spectra. In high-throughput screening where large libraries of compounds are tested for biological activity, the number of samples runs easily into the millions. The latest generation of MALDI-MS is specifically designed for these heavy duty tasks. In this presentation the technological innovations will be discussed and the  performance will be  illustrated with real-life applications.

About Rob van der Heijden

Rob van der Heijden studied pharmacy at the University of Amsterdam. Between 1984 and 2008 he held different positions at Leiden University.  He obtained his PhD in 1989 at the Division of Pharmacognosy, Leiden/Amsterdam Center for Drug Research.  In 2000 he joined the Division of Analytical Biosciences (LACDR). His scientific interest is in the development and application of analytical methodology (chromatography, mass spectrometry) for the analysis of small molecules (metabolomics) and proteins (proteomics). Since 2008 he is appointed as application support scientist for mass spectrometry at Bruker Nederland BV, NL.